This double blind randomised study tested the effectiveness of colloidal bismuth subcitrate (De-Nol) 
Non-ulcer dyspepsia (NUD) is poorly understood and often present in association with gastritis. '" Among patients undergoing gastroscopy approximately half with NUD have a gastric mucosa colonised by Cpylori and there is evidence suggesting that it may play a pathogenic role in NUD."' Little is known, however, about the value of De-Nol in the treatment of NUD and therefore we undertook a placebo controlled trial to examine whether De-Nol is effective in the treatment of NUD and whether any benefit is associated with the clearance of C pylori from the gastric mucosa.
Methods

PATIENTS
Over the past 18 months 66 patients (42 men, mean age 39-1 years, range were included in the trial, The series comprised consecutive patients with upper GI dyspeptic symptoms, whose gastroscopy was either normal or showed minor inflammatory features in the antrum (usually patchy erythema), who conformed to the inclusion criteria and who gave their informed consent to take part in the trial. Patients were excluded from the study if they had peptic ulceration, neoplasm, erosive or ulcerative oesophagitis, recently consumed non-steroidal antiinflammatory drugs (NSAID), been treated with H2 blockers within seven days of endoscopy, debilitating disease, previous gastric surgery, renal insufficiency, pregnancy or breast feeding, or were unable to cooperate. No patient had prominent bowel symptoms suggesting the irritable bowel syndrome. The study was approved by Guy's Medical School ethical committee.
STUDY DESIGN
After gastroscopy patients were questioned by one of the authors (TR) about the presence of dyspeptic symptoms -that is, epigastric pain, nausea, vomiting, heartburn, halitosis, postprandial bloating, and flatulence. They were also questioned about smoking and alcohol consumption. The patient's overall well being was quantified using a scale from 0 to 100, with 0 representing no symptoms and 100 representing severe, unbearable symptoms. Subsequently the patients were randomly allocated to eight weeks treatment with either De-Nol (two tablets to be taken twice daily, half an hour before breakfast and dinner with a drink of water -that is, a total dose of 480 mg) or matching placebo (two tablets to be taken twice daily, half an hour before meals with water). Blindness was attempted by providing medication and instructions in identical sealed boxes and only a minority remarked on changes of taste or faecal colour (see side effects). In addition all patients were given a supply of antacid tablets (Gelusil) for symptomatic relief and a diary on which to record daily the presence or absence of epigastric pain, its duration, and the number of antacid tablets taken. In addition they were given instructions to avoid drugs such as NSAID, antibiotics, and H2-blockers during the trial. At this stage an abdominal ultrasound was arranged for all patients and those who were found to have pathology to which the dyspeptic symptoms 1 ). This improvement was associated with a good symptomatic response in the C pylori positive subgroup (n= 12) in which the symptom score before treatment (63.5 (4.11)) was significantly worse than after treatment (16 (5) p<0001). In this subgroup De-Nol completely resolved the symptoms in five of 12 (41.6%) patients. The C pylori negative patients (n=13) did not show any improvement in that the symptom scores before treatment (56.3 (5)) were similar to those after treatment (48.23 (5)).
In contrast with De-Nol, placebo did not succeed in improving symptoms in the whole group (n=27), De (Fig. 1) .
In the De-Nol and placebo subgroups of C pylori positive patients, comparison of weekly pain free days showed that these two groups did not differ significantly for the first three weeks and became significant thereafter, reaching highly significant levels by the end of treatment (Fig. 2) .
The consumption of antacids during the trial for pain relief in the two subgroups of C pylori positive patients was similar for the first three weeks and became significant during the remaining weeks (Fig.  3) .
In the whole group of 66 patients there was a significant association between C pylori and postprandial bloating (x2=5*33, p<0-05). In the subgroup of C pylori positive patients De-Nol abolished postprandial bloating in eight of 10 patients with this symptom (p=0.002) whereas placebo did not.
HISTOLOGICAL RESPONSE
In the whole group of patients De-Nol significantly improved gastric mucosal histology (activity before treatment 1.12 (0.22) v 0.56 (0.15) after treatment, p<0-001) and this was due to the fact that 10 of the 12 C pylori positive patients who became negative after treatment had significant improvement in their histology (activity before treatment 2.08 (0.20) v 1*08 (0.22) after treatment, p<0001) (Fig. 4) . In detail three of these 10 patients (30%) had complete morphological restoration after treatment and seven (70%) had significant improvement. The other two C pylori positive patients who did not change histology after treatment were those in whom De-Nol did not clear Cpylori. In contrast with De-Nol, placebo did not succeed in improving the histological picture either in the whole group (activity before treatment 1-03 (0.18) v 1-22 (0-18) after treatment, NS), or in the subgroup of the C pylori positive patients (activity before treatment 2 (0.26) v 1.62 (0.32) after treatment, NS) (Fig. 4) .
PATIENTS WHO BECAME C PYLORI POSITIVE DURING TREATMENT
In the placebo group seven of the 19 Cpylori negative patients before treatment (36.8%) were found to have C pylori positive cultures at the end of treatment. No C pylori negative patients became positive in the De-Nol group and the difference between the two groups in Cpylori negative patients who became positive was significant (x2=7.1, p<0-01). In these seven patients the symptom scores after treatment (72-85 (2.72)) were significantly worse (p<002) than those before treatment (41.85 (0.93)) (Fig. 1) . Similarly, in this group of patients, histology after treatment (1-85 (0.26)) was significantly worse (p<0.02) than before treatment (0.85 (0.26)) ( the tablets. None of these three patients considered this as an unacceptable problem and did not discontinue the medication. Two others mentioned that their faeces were very dark. One patient in the placebo group developed severe diarrhoea and it was thought that the treatment should be stopped.
Discussion
Non-ulcer dyspepsia is a poorly understood syndrome often present in association with gastritis'7 and among patients undergoing gastroscopy approximately half with NUD have a gastric mucosa colonised by C pylori. '4 We confirmed this in an earlier study,'8 which included many but not all the patients reported here but which was not concerned with treatment. Our studies also confirmed the strong association between the presence of C pylori in the gastric mucosa and histological gastritis."-' Several investigators have recently successfully used bismuth salts and other antimicrobial agents in the treatment of Cpylori associated gastritis'5 16 and in these studies clearance from the gastric mucosa was accompanied by resolution or significant improvement of histological gastritis. In our study De-Nol, as opposed to placebo, was successful in clearing C pylori from the gastric mucosa of patients with positive cultures with a significant improvement of gastritis. This strengthens the possibility that C pylori may play a role in the pathogenesis of NUD.
We also found a significant symptomatic improvement in the De-Nol group as opposed to placebo. This improvement was because of the highly significant amelioration of symptoms in the C pylori positive patients who obtained relief from epigastric pain by the end of the third week of therapy and reached high levels of statistical significance by the end of treatment. This was accompanied by a significant reduction in antacid consumption which started at the end of the third week and became highly significant by the end of treatment. On the contrary the C pylori negative patients, the majority of whom had normal histology, did not experience symptomatic improvement.
In this study we confirmed a significant association between C pylori and postprandial bloating'8 and found that De-Nol as opposed to placebo abolished this symptom in a significant number of patients in parallel with C pylori clearance. This strongly suggests that C pylori infection was responsible for postprandial bloating and this might be the result of C pylori producing urease which would liberate carbon dioxide from urea present in the gastric mucosa. '821 The antimicrobial activity of bismuth salts'5 or their mucosal protective effect22 could explain the effectiveness of De-Nol in the C pylori positive patients. Studies of gastric biopsies by electron microscopy23 have shown that bismuth salts coat the C pylori present in the gastric crypts and this is followed by swelling and lysis of the bacteria. This proves that bismuth salts penetrate the mucus layer and reach the gastric crypts in sufficient concentrations to kill C pylori. On the other hand sucralfate, which is a gastric mucosal protective agent,24 is not active against Cpylorl5 and does not clear it from the gastric mucosa or have any effect on histological gastritis. 26 The ineffectiveness of a purely mucosal protective agent to improve gastritis strongly suggests that it is the antimicrobial activity of De-Nol that is important.
In this study seven C pylori negative patients receiving placebo were found to be positive at the end of treatment and this change from negative to positive status was associated with significant deterioration in their symptoms and gastritis which stresses the pathogenic role of this organism as suggested elsewhere.'4 Five of these seven patients had gastritis initially and may have been colonised by C pylori which was for some reason undetected. It is also possible that these patients were infected by C pylori contaminated fibreoptic endoscopes. The symptomatic deterioration supports the latter explanation. The efficacy of Teepol and Cidex against C pylori requires formal study. The fact that no C pylori negative patients in the De-Nol group became positive stresses the effectiveness of this drug against Cpylori.
No serious side effects were observed with De-Nol and the bismuth levels at the end of treatment were well below the therapeutically acceptable upper limits." This confirms that De-Nol is a safe drug as stressed elsewhere.
In conclusion, this study shows that short term DeNol treatment, as opposed to placebo, is successful in treating symptoms and healing the gastritis in NUD. In the C pylori positive group in particular, De-Nol successfully cleared C pylori from the gastric mucosa with significant improvement of symptoms and associated gastritis. This is in agreement with studies on NUD Cpylori positive patients reported by others in abstract form.?829 Because endoscopy is unreliable for detecting gastritis in NUD patients '7 11 its main value is in obtaining specimens for histological and bacteriological processing and when cultures are positive for C pylori, De-Nol administration is recommendable. It remains to be established whether the clearance of C pylori and the associated histological and symptomatic improvement persists after a short course of De-Nol.
